Segment Overview: Dr. Howard (Jack) West, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, talks about scientific advancements that are transforming the understanding of NSCLC ALK Positive or anaplastic lymphoma kinase-positive (ALK+) non small cell lung cancer (NSCLC). He also talks about his involvement with the Takeda Pharmaceutical’s launch of tALK+ (Talk Positive), an initiative during November Lung Cancer Awareness Month. Patients and their families, doctors and researchers to get involved in the tALK+ conversation by following @TakedaOncology on Facebook, Twitter and Instagram and sharing positive insights and personal stories of those impacted by ALK+ NSCLC to recognize the significant moments and/or people who have made a positive impact in their lives using the social media hashtag #tALKpositiveNSCLC.
Guest: Dr. Howard West
Presenter: Neal Howard
Guest Bio: Dr. Howard West is a medical oncologist in Seattle, Washington, where he works at Swedish Cancer Institute and has a specific focus on thoracic oncology. He received his medical degree and internal medicine training at Harvard and then moved to Seattle for his fellowship in medical oncology at the University of Washington/Fred Hutchinson Cancer Research Center. He also serves as the Web Editor for JAMA Oncology and is the founder and President of the education non-profit for patients, GRACE: Global Resource for Advancing Cancer Education